Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: A Southwest Oncology Group study

Gynecologic Oncology

Volumn 95, Issue 1, 2004, Pages 145-151

  Lavey, Robert S ^a   Liu, P Y ^b   Greer, Benjamin E ^c   Robinson III, William R ^d   Chang, Pui C ^e   Wynn, Raymond B ^f   Conrad, Marcel E ^g   Jiang, Caroline ^b   Markman, Maurie ^h   Alberts, David S ⁱ  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SW Oncology Group Statistical Center   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Harrington Cancer Center   (United States)

^e TULANE UNIVERSITY   (United States)

^f LOUISIANA STATE UNIVERSITY   (United States)

^g Gulf Coast Minority Based Comm C   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITY OF ARIZONA   (United States)

Author keywords

Anemia; Cervix cancer; Chemotherapy; Erythropoietin; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FERRITIN; HEMOGLOBIN; IRON; IRON SACCHARATE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ACUTE TOXICITY; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEARING LOSS; HEMOGLOBIN DETERMINATION; HUMAN; IRON BLOOD LEVEL; IRON THERAPY; LUNG TOXICITY; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MITRAL VALVE DISEASE; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION SICKNESS; STATISTICAL SIGNIFICANCE; STROKE; TRANSFERRIN BLOOD LEVEL; URETER OBSTRUCTION; UROGENITAL TRACT DISEASE; UTERINE CERVIX CARCINOMA;

EID: 4644220200     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.07.009     Document Type: Article

References (37)

1. A. Jemal, T. Murry, A. Samuels, A. Ghafoor, E. Ward, and M.J. Thun Cancer statistics Clin. C. A. Cancer J. 53 2003 5 26
2. D.T. Janerich, O. Hadjimichaelo, and P.E. Schwartz The screening histories of women with invasive cervical cancer, Connecticut M.J. Public Health 85 1995 791 794
3. SEER cancer incidents public use data base, 1973â€"1994 1997 National Cancer Institute Bethesda MD (software)
4. M. Grogan, G.M. Thomas, I. Melamed, F.L.W. Wong, R.G. Pearcey, and P.K. Joseph The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix Cancer 86 1999 1528 1536
5. J.M. Thomson, and J.S. Spratt Factors affecting survival in over 500 patients with stage II carcinoma of the cervix Radiology 123 1977 181 183
6. D.X. Kapp, D. Fischer, E. Gutierrez, E.I. Kohorn, and P.E. Schwartz Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariate analysis of the effect of age, stage, histology and blood counts on survival Int. J. Radiat. Oncol. Biol. Phys. 9 1983 445 455
7. R.S. Bush, R.D. Jenkin, W.E. Allt, F.A. Beale, H. Bean, and A.J. Dembo Definitive evidence for hypoxic cells influencing cure in cancer therapy Br. J. Cancer 37 Suppl. III 1978 302 306
8. S. Dische, P.J. Anderson, R. Sealy, and E.R. Watson Carcinoma of the cervix-anemia, radiotherapy and hyperbaric oxygen Br. J. Radiol. 56 1983 251 255
9. J. Evans, and P. Bergso The influence of anemia on the results of radiotherapy in carcinoma of the cervix Raidology 48 1965 709 717
10. T. Girinski, M.H. Pejovic-Lenfant, J. Bourhis, F. Campana, J.M. Cosset, and C. Petit Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retro-spective study of 386 patients Int. J. Radiat. Oncol., Biol., Phys. 16 1989 37 42
11. P. Hierlihy, R.D. Jenkin, and J.A. Stryker Anemia as a prognostic factor in cancer of the cervix: a preliminary report Can. Med. Assoc. J. 100 1969 1100 1102
12. P. Schreiner, E. Siracka, J. Siracka, and I. Manka The effect of anemia on the radiotherapy results of the uterine cervix cancer Neoplasma 22 1975 655 660
13. G. Vigario, S.S. Kurohara, and F.W. George Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer Radiology 106 1973 649 652
14. H.C. Hsuan, S.W. Leung, E.Y. Huang, C.J. Wang, L.M. Sun, and H.C. Chen Impact of the extent of parametrial involvement in patients with carcinoma of the uterine cervix Int. J. Radiat. Oncol., Biol., Phys. 40 1998 405 410
15. W.M. Mendenhall, T.L. Thar, F.J. Bova, R.B. Maracus, L.S. Morgan, and R.R. Million Prognostic and treatment factors affecting pelvic control of stage IB and IIA-B carcinoma of the intact uterine cervix treated with radiation therapy alone Cancer 53 1984 2649 2654
16. L.S. Freedman, D.J. Honess, N.M. Bleehen, G.E. Adams, and S. Dische Does initial haemoglobin level modify the efficacy of radiosensitizers? An analysis of the MRC misonidazole studies in head and neck cancer and cervix cancer Int. J. Radiat. Biol. 52 1987 963 967
17. J. Overgaard, S.M. Bentzen, P. Kolstad, K. Kjoerstad, M. Davy, and K. Bertelsen Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix Int. J. Radiat. Oncol., Biol., Phys. 16 1989 1069 1072
18. O. Solberger, and B. Sorbe Fever, haemoblobin and smoking as a prognostic factors during the treatment of cervical carcinoma by radiotherapy Eur. J. Gynaecol. Oncol. 11 1990 97 102
19. J.S. Rader, D.J. Haraf, H.J. Halpern, J. Rotmensch, D.R. Spelbring, and H. Sutton Radiation therapy in the treatment of cervical cancer: the University of Chicago/Michael Reese Hospital experience J. Surg. Oncol. 44 1990 157 165
20. R. Tan, C.H. Chung, M.T. Liu, Y.L. Lai, and K.H. Chan Results of postoperative radiotherapy for clinical stage IB uterine cervical carcinoma with evidence of microscopic involvement of surgical margin, parametrium and/or lymph node metastasis J. Formosan Med. Assoc. 90 1991 836 839
21. M. Chatani, Y. Matayoshi, N. Masaki, T. Teshima, and T. Inoue Long term follow-up results of high-dose rate remote afterloading intracavitary radiation therapy for carcinoma of the uterine cervix Strahlenther. Onkol. 170 1994 269 276
22. J. Dunst, T. Kuhnt, G. Strauss, U. Krause, T. Pelz, and H. Koelbl Anemia in cervical cancers: impact on survival, patterns of relapse and association with hypoxia and angiogenesis Int. J. Radiat. Oncol., Biol., Phys. 56 2003 778 787
23. M. Werner-Wasik, C.H. Schmid, L. Bornstein, H.G. Ball, D.M. Smith, and H. Madoc-Jones Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma Int. J. Radiat. Oncol., Biol., Phys. 32 1995 1309 1317
24. R.S. Bush The significance of anemia in clinical radiation therapy Int. J. Radiat. Oncol., Biol., Phys. 12 1986 2047 2050
25. R.S. Lavey, and W.H. Dempsey Erythropoietin increases hemoglobin in cancer patients during radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 27 1993 1147 1152
26. P.J. Sweeney, D. Nicolae, L. Ignacio, L. Chen, M. Roach, and M. Wara Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labeled, phase II trial Br. J. Cancer 77 1998 1996 2001
27. C.H. Glaser, W. Millesi, G.V. Kornek, S. Lang, B. Schull, and K. Klug Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx Int. J. Radiat. Oncol. Biol. Phys. 50 2001 705 715
28. K.A. Dusenbery, W.A. McGuire, P.J. Holt, L.F. Carson, J.M. Fowler, and L.B. Twiggs Erythropoietin increases hemoglobin during radiation therapy for cervical cancer Int. J. Radiat. Oncol., Biol., Phys. 29 1994 1079 1084
29. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response J. Clin. Oncol. 1 1983 710 719
30. D. Henry, B. Mason, A. Staddon, P. Ford, B. Matthews, and M. Moore Efficacy of Infed® plus recombinant human erythropoietin (rHuEPO) in treating anemia in cancer patients with suboptimal response to rHuEPO: a pilot study Proc. ASCO 17 1998 59a
31. M. Auerbach, H. Ballard, R. Trout, M. McIlwain, A. Ackerman, and H. Bahrain Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial J. Clin. Oncol. 22 2004 1301 1307
32. P.G. Rose, B.N. Bundy, E.B. Watkins, J.T. Thigpen, G. Deppe, and M.A. Maiman Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N. Engl. J. Med. 340 1999 1144 1153
33. M. Henke, R. Laszig, C. Rube, U. Schafer, K.D. Haase, and B. Schilcher Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiation therapy: randomized, double-blind, placebo-controlled trial Lancet 362 2003 1255 1260
34. B. Leyland-Jones Breast cancer trial with erythropoietin terminated unexpectedly Lancet. Oncol. 4 2003 459 460
35. T.J. Littlewood, E. Bajetta, J.W.R. Nortier, E. Vercammen, and B. Rapoport Effects of epoietin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J. Clin. Oncol. 19 2001 2865 2874
36. T. Wun, L. Law, D. Harvey, B. Sieracki, S.A. Scudder, and J.K. Ryu Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin Cancer 98 2003 1514 1520
37. M. Rosenzweig, C.M. Bender, J.P. Lucke, J.M. Yasko, and A.M. Brufsky Increased thrombotic events in a clinical trial of erythropoietin (EPO) in metastatic breast cancer Proc. ASCO 21 2002 381